Lomustine
Gleostine (lomustine) is a small molecule pharmaceutical. Lomustine was first approved as Gleostine on 1982-01-01. It is used to treat brain neoplasms, colonic neoplasms, hodgkin disease, kidney neoplasms, and lung neoplasms amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Gleostine (discontinued: Gleostine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lomustine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GLEOSTINE | CordenPharma | N-017588 RX | 1982-01-01 | 3 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| gleostine | New Drug Application | 2024-01-23 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0178 | Lomustine, oral, 10 mg |
Clinical
Clinical Trials
131 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | — | 8 | — | 1 | 1 | 10 |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | — | 1 | 1 | 3 | 5 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 4 | — | 1 | — | 5 |
| Graft vs host disease | D006086 | — | D89.81 | — | 1 | — | 1 | — | 2 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 1 | — | 1 | — | 2 |
| Virus diseases | D014777 | — | B34 | — | — | — | 1 | — | 1 |
| Retinal diseases | D012164 | HP_0000479 | H35.9 | — | — | — | 1 | — | 1 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | 1 | — | 1 |
| B-cell lymphoma | D016393 | — | — | — | — | — | 1 | — | 1 |
| Burkitt lymphoma | D002051 | — | C83.7 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 10 | 30 | 17 | — | 5 | 53 |
| Recurrence | D012008 | — | — | 4 | 10 | 7 | — | 5 | 22 |
| Central nervous system neoplasms | D016543 | — | — | 2 | 7 | 11 | — | 3 | 22 |
| Nervous system neoplasms | D009423 | — | — | 2 | 7 | 11 | — | 2 | 21 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 5 | 7 | 5 | — | 1 | 16 |
| Medulloblastoma | D008527 | — | — | 2 | 7 | 5 | — | 2 | 14 |
| Leukemia | D007938 | — | C95 | — | 5 | 7 | — | 3 | 13 |
| Glioma | D005910 | EFO_0000520 | — | 3 | 4 | 6 | — | 1 | 13 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | 4 | 7 | — | 1 | 12 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 3 | 4 | — | 1 | 7 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | — | 1 | — | — | 2 | 3 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 2 | — | — | 1 | 3 |
| Melanoma | D008545 | — | — | 2 | 1 | — | — | — | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 1 | — | — | — | 2 |
| Hodgkin disease | D006689 | — | C81 | — | 2 | — | — | — | 2 |
| Ependymoma | D004806 | — | — | — | 1 | — | — | 1 | 2 |
| Primitive neuroectodermal tumors | D018242 | — | — | — | 1 | — | — | 1 | 2 |
| Neuroectodermal tumors | D017599 | — | — | — | 1 | — | — | 1 | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
Show 18 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Meningeal carcinomatosis | D055756 | EFO_1001012 | — | 1 | — | — | — | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoid leukemia | D007945 | — | C91 | — | — | — | — | 2 | 2 |
| Acute disease | D000208 | — | — | — | — | — | — | 1 | 1 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | — | — | — | — | 1 | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | — | 1 | 1 |
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | — | — | 1 | 1 |
| Small cell lung carcinoma | D055752 | — | — | — | — | — | — | 1 | 1 |
| Classical conditioning | D003214 | — | — | — | — | — | — | 1 | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lomustine |
| INN | lomustine |
| Description | Lomustine is an N-nitrosourea that is urea in which one of the nitrogens is substituted by a 2-chloroethyl group and by a nitroso group, while the other nitrogen is substituted by a cyclohexyl group. An alkylating antineoplastic agent, it is used in the treatment of brain tumours, lung cancer, malignant melanoma and other solid tumours. It has a role as an alkylating agent and an antineoplastic agent. It is a member of N-nitrosoureas and an organochlorine compound. |
| Classification | Small molecule |
| Drug class | antineoplastics (chloroethylamine derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=NN(CCCl)C(=O)NC1CCCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 13010-47-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL514 |
| ChEBI ID | 6520 |
| PubChem CID | 3950 |
| DrugBank | DB01206 |
| UNII ID | 7BRF0Z81KG (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Lomustine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,244 documents
View more details
Safety
Black-box Warning
Black-box warning for: Gleostine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,829 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use